|1.||Nakagawa, Fumio: 8 articles (09/2015 - 02/2004)|
|2.||Fukushima, Masakazu: 6 articles (10/2008 - 04/2004)|
|3.||Peters, Godefridus J: 4 articles (11/2015 - 01/2007)|
|4.||Kuwata, Keizo: 4 articles (08/2015 - 09/2006)|
|5.||Okabe, Hiroyuki: 4 articles (05/2015 - 02/2004)|
|6.||Emura, Tomohiro: 4 articles (09/2004 - 02/2004)|
|7.||Yamazaki, Kentaro: 3 articles (10/2015 - 10/2012)|
|8.||Ohtsu, Atsushi: 3 articles (10/2015 - 10/2012)|
|9.||Yoshino, Takayuki: 3 articles (10/2015 - 10/2012)|
|10.||Takechi, Teiji: 3 articles (09/2015 - 03/2015)|
|1.||Colorectal Neoplasms (Colorectal Cancer)
05/14/2015 - "In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival. "
04/01/2015 - "Although TAS-102 was effective for the treatment of refractory metastatic colorectal cancer in clinical trials, the mechanism of FTD-induced cytotoxicity is not completely understood. "
11/01/2015 - "TAS-102 has demonstrated efficacy in 5-FU-refractory patients based on a different mechanism of action and has been approved for the treatment of metastatic colorectal cancer in Japan. "
11/01/2015 - "Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer."
11/01/2015 - "This schedule showed consistent activity in two randomized trials on fluoropyrimidine refractory colorectal cancer patients, reflected by an increase of 2-3 months in overall survival in the TAS-102 group compared with placebo. "
10/01/2008 - "Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors."
11/01/2015 - "Considering the impressive preclinical potential of various combinations TAS-102 has the promise to become an alternative for 5FU-resistant cancer. "
05/01/2015 - "[(18)F]FLT PET has a potential to assess the pharmacodynamics of TAS-102 in cancer patients."
12/01/2014 - "TAS-102 reduced the Ki-67-positive cell fraction, and swollen nuclei were observed in treated tumor tissue. "
05/01/2010 - "TAS-102 has been shown to exhibit antitumor activity in fluoropyrimidine-resistant human cancer cells. "
|3.||Stomach Neoplasms (Stomach Cancer)
11/01/2008 - "TFT, as part of TAS-102, has been clinically evaluated as an oral chemotherapeutic agent in colon and gastric cancer. "
09/01/2015 - "In the present study, the enhancement of therapeutic efficacy using a combination of TAS-102 and oxaliplatin was evaluated in a xenograft-bearing nude mouse model of colorectal and gastric cancer. "
03/01/2015 - "In the present study, enhancement of the therapeutic efficacy using a combination therapy of TAS-102 and irinotecan hydrochloride (CPT-11) was evaluated in a colorectal and gastric cancer xenograft-bearing nude mouse model. "
09/01/2015 - "The tumor growth-inhibitory activity and RTV5 in mice administered TAS-102 with oxaliplatin were significantly superior to those associated with either monotherapy in mice with colorectal (HCT 116, SW-48; p<0.001) and gastric cancer (SC-2, MKN74; p<0.001). "
09/01/2015 - "Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts."
|4.||Colonic Neoplasms (Colon Cancer)
01/15/2007 - "TAS-102 is only effective in inducing cytotoxicity when systemic TPI is present, but acts against both low and high TP expressing colon cancer cells, while 5'DFUR needs cellular TP to exert significant activity."
05/01/2015 - "Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment."
01/15/2007 - "We used the model to study the in vivo role of thymidine phosphorylase/platelet-derived endothelial cell growth factor (TP/PD-ECGF) in the cytotoxicity and pharmacodynamics of TAS-102 in colon cancer cells. "
01/01/2014 - "TAS-102 (trifluorothymidine [TFT] and thymidine phosphorylase inhibitor [TPI] in a molar ratio of 1:0.5) has activity in 5-fluorouracil resistant colon cancer. "
|5.||Pancreatic Neoplasms (Pancreatic Cancer)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Combination Drug Therapy (Combination Chemotherapy)
|3.||Drug Therapy (Chemotherapy)